3Heijmink SW, Futterer JJ , Hambrock T, et al. Prostate canc- er:body- array versus eadorectal coil MR imaging at 3 T- comparison of image quality, localization, and staging pedor- mance [ J ]. Radiology, 2007,244 ( 1 ) : 184 - 195.
4Gontero P, Marchioro G, Pisani R, et al. Is radical prostatec-tomy feasible in all cases of locally advanced non - bone me- tastatic prostate cancer? [ J ]. Eur Urol,2007,51 (4) :922 - 930.
5Van Poppel H, Vekemans K, Da pozzo L, et al. Radical pros- tatectomy for locally advanced prostate cancer: results of a feasibility study( EORTC 30001 ) [ J ]. Eur J Cancer, 2006. 42 ( 8 ) : 1062 - 1067.
6Joniau S, Van Baelen A, Hsu C, et al. Treatment of clinical stage 33 prostate cancer:a surgical disease? [ J ]. Eur Urol Suppl,2006,5 (2) :213.
7Joniau SG, Van Baelen AA, Hsu CY, et al. Compications and functional results of surgery for locally advanced prostate cancer [ J ]. Adv Urol,2012 (2012) Article ID 706309.
8Hsu CY, Joniau S , Van Poppel H , et al . Comparing resuhs after surgery in patients with clinical unilateral 33a prostate cancer treated with or without neoadjuvant androgen - depri- vation therapy. BJU Int, 2007,99 (2) : 311 - 314.
9Dreicer R, Magi -Galluzzi C ,Zhou M, et al. Phase Ⅱ trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology, 2004,63 ( 6 ) : 1138 - 1142.
10Febbo PG, Richie JP, George DJ , et al. Neoadiuvant do- cetaxel before radical prostatectomy in patients with high - risk localized prostate cancer . Clin Cancer Res, 2005,11(14) :5233 - 5240.
5Nelson JE, Harris RE. Inverse association of prostate cancer and nonsteroidal antiinflammatory drugs results of case-control study [J]. Oncol Rep,2000,7( 1 ) :169-170.
6Thun MJ, Namboodiri MM, Heath CM. Aspirin use and reduced risk of fatal colon cancer[J]. N Engl J Med,1991,325(23): 1593-1596.
7Di Sario JA, Alberts DS,Tretze CC, et al. Sulindac induces regression and prevents progression of sporadic colorectal adenomas [ J ]. Gastroenterology, 1997,112 (6) : 1284-1290.
9Mofita I, Schindler M, Regier MK, et al. Differential intracellular locations for prostaglandin endoperoxide H synthase-1 and -2 [ J ]. J Biol Chem, 1995,270( 18 ) : 10902-10908.
10Sternlicht MD, Bergers G. Matrix metalloproteinases as emerging targets in anticancer therapy : status and prospects [ J ]. Emerg Therapeut Targets, 2000,4(5 ) :609-633.
